ATE330620T1 - Verwendung von midkin oder von anti-midkin antikörper - Google Patents

Verwendung von midkin oder von anti-midkin antikörper

Info

Publication number
ATE330620T1
ATE330620T1 AT98931102T AT98931102T ATE330620T1 AT E330620 T1 ATE330620 T1 AT E330620T1 AT 98931102 T AT98931102 T AT 98931102T AT 98931102 T AT98931102 T AT 98931102T AT E330620 T1 ATE330620 T1 AT E330620T1
Authority
AT
Austria
Prior art keywords
midkin
antibodies
midkine
inducible
heparin
Prior art date
Application number
AT98931102T
Other languages
English (en)
Inventor
Takashi Muramatsu
Tohru Takada
Kazuhiro Toriyama
Hisako Muramatsu
Original Assignee
Takashi Muramatsu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takashi Muramatsu filed Critical Takashi Muramatsu
Application granted granted Critical
Publication of ATE330620T1 publication Critical patent/ATE330620T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AT98931102T 1997-07-14 1998-07-14 Verwendung von midkin oder von anti-midkin antikörper ATE330620T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20532097 1997-07-14
JP20533297 1997-07-14

Publications (1)

Publication Number Publication Date
ATE330620T1 true ATE330620T1 (de) 2006-07-15

Family

ID=26515003

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98931102T ATE330620T1 (de) 1997-07-14 1998-07-14 Verwendung von midkin oder von anti-midkin antikörper

Country Status (10)

Country Link
US (1) US7390491B2 (de)
EP (1) EP0998941B9 (de)
JP (1) JP2010215673A (de)
KR (1) KR100571010B1 (de)
CN (1) CN1287852C (de)
AT (1) ATE330620T1 (de)
AU (1) AU756279B2 (de)
CA (1) CA2296409C (de)
DE (1) DE69835016T2 (de)
WO (1) WO1999003493A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139030A0 (en) * 1998-04-17 2001-11-25 Angiogenix Inc Therapeutic angiogenic factors and methods for their use
KR100608276B1 (ko) * 1998-08-24 2006-08-02 무라마쯔 다카시 동맥경화 및 ｐｔｃａ술후의 혈관 재협착에 대한예방·치료제
US20060259026A1 (en) * 2005-05-05 2006-11-16 Baylis Medical Company Inc. Electrosurgical treatment method and device
JP4768440B2 (ja) * 2003-03-06 2011-09-07 セルミド リミテッド 開腹手術後の癒着の予防剤
WO2004085642A1 (ja) * 2003-03-27 2004-10-07 Takashi Muramatsu 関節炎関連遺伝子及びこれの関節炎検査等への利用
JP5398987B2 (ja) * 2005-11-14 2014-01-29 セルミド リミテッド 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法
CA2669523C (en) * 2006-11-14 2016-06-21 Ribomic Inc. Aptamer against midkine and use thereof
EP2088159B1 (de) 2006-11-14 2014-03-05 Medical Therapies Limited Die c-domäne von midkin erkennenden antikörpern
WO2010074218A1 (ja) * 2008-12-25 2010-07-01 株式会社イーベック 抗ヒトミッドカイン抗体
US20110212181A1 (en) * 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
US9624294B2 (en) 2011-03-14 2017-04-18 Cellmid Limited Antibody recognizing N-domain of midkine
AU2013297478B2 (en) 2012-07-30 2018-12-20 Medical & Biological Laboratories Co., Ltd. Monoclonal antibody against human midkine
KR101985300B1 (ko) * 2016-07-19 2019-06-03 삼성전자주식회사 미드카인 저해제를 포함하는 뇌종양 치료 또는 예방용 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206223A (en) 1986-06-26 1993-04-27 Yeda Research And Development Co. Ltd. Method for inhibiting heparanase activity
IL79254A0 (en) * 1986-06-26 1986-09-30 Hadassah Med Org Compositions for preventing graft rejection
US5210026A (en) 1990-08-20 1993-05-11 American Cyanamid Company Human mk gene and method of expression
DE69232615T2 (de) 1991-05-02 2003-01-30 Cohen, Irun R. Zusammensetzungen zur verhütung und/oder behandlung von pathologischen prozessen
EP0535336A3 (en) * 1991-09-30 1993-05-19 American Cyanamid Company Mk protein as cell growth inhibitor
US5461029A (en) * 1992-04-24 1995-10-24 American Cyanamid Company Method of treating herpes viral infections using HBNF and MK proteins
AU7205894A (en) * 1993-06-08 1995-01-03 Neogenix, Inc. Purified natural and synthetic compounds for the treatment of osteoarthritis
EP0754460B1 (de) 1995-02-07 2002-06-05 Shiseido Company Limited Anti-inflamatorische agenzien
JPH08277224A (ja) * 1995-02-07 1996-10-22 Shiseido Co Ltd 抗炎症剤
US5629284A (en) * 1995-07-24 1997-05-13 Meiji Milk Products Co., Ltd. Method for treating retinal diseases
JPH0995454A (ja) 1995-10-02 1997-04-08 Meiji Milk Prod Co Ltd 抗潰瘍組成物
CA2260014A1 (en) 1996-07-10 1998-01-15 Meiji Milk Products Co., Ltd. Novel use of mk family as hematopoietic factor

Also Published As

Publication number Publication date
WO1999003493A1 (fr) 1999-01-28
CA2296409A1 (en) 1999-01-28
EP0998941B1 (de) 2006-06-21
AU756279B2 (en) 2003-01-09
DE69835016T2 (de) 2007-06-28
AU8131098A (en) 1999-02-10
EP0998941A4 (de) 2004-05-12
US20030072739A1 (en) 2003-04-17
KR100571010B1 (ko) 2006-04-13
JP2010215673A (ja) 2010-09-30
CN1306435A (zh) 2001-08-01
CN1287852C (zh) 2006-12-06
EP0998941A1 (de) 2000-05-10
EP0998941B9 (de) 2007-03-14
DE69835016D1 (de) 2006-08-03
US7390491B2 (en) 2008-06-24
KR20010021814A (ko) 2001-03-15
CA2296409C (en) 2010-05-18

Similar Documents

Publication Publication Date Title
DE69835016D1 (de) Verwendung von midkin oder von anti-midkin antikörper
DE3667378D1 (de) Verwendung von n-(4-phenoxy-2,6-diisopropylphenyl)-n'-tert.butylthioharnstoff zur bekaempfung von weissen fliegen.
ATE454141T1 (de) Guanylhydrazone die nützlich sind zur behandlung von mit t-zellen verbundenen krankheiten
FI946004A0 (fi) Lääketieteellisessä toimenpiteessä käytettävä trombiiniverifraktio
FI920992A (fi) Foerfarande foer framstaellning av i industriell skala av ett standardiserat koncentrat av human von willebrand-faktor, vilket har synnerligen hoeg renhet och aer laempligt foer terapeutisk anvaendning
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
ATE295414T1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
ATE413885T1 (de) Getrocknete blutfaktorzusammensetzung mit trehalose
ATE339505T1 (de) Antagoniste von interleukin-15
CO4830493A1 (es) Anticuerpos contra cd40 humano
ATA76995A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen
ATE198895T1 (de) Verwendung von bindungsreagenzien gegen cd23 in der behandlung von autoimmunkrankheiten
DE69001839D1 (de) 1-hydroxyvitamin d2-epimer und dessen derivate.
EA199900279A1 (ru) Производные бензамида и их применение в качестве лекарственных средств с лтв4-антагонистической активностью
DE3774858D1 (de) Derivate von n-(2-alkyl-3-mercaptoglutaryl)-alpha-aminosaeuren und deren verwendung als collagenase-inhibitoren.
DE3680000D1 (de) Stabilisierte aktive formen von vitamin-d3.
DE69624707D1 (de) Therapeutische verwendung von 1-amino-3-(n,n-dimethylamino)-propyliden-1,1-bisphosphonsäure und ihre salze
ATE208042T1 (de) Hapten-analoge zur verwendung in immunoassays
DE59806627D1 (de) Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
BR9612074A (pt) Novos 4-(1h-benzimidazol-2-il)(1,4) diazepanos substituidos úteis para o tratamento de doenças alérgicas
BR9612196A (pt) Tiazolinas substituidas
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
ATE341293T1 (de) Kortikalknochenimplantat für wirbelfusion nach smith-robinson
DE69227805D1 (de) Verwendung von Tri-n-Butylphosphat bei niedrigem pH in Lösungen von biologisch aktiven Proteinen für eine verbesserte viruzide Wirkung
DE3871712D1 (de) Suspensionen und verwendung dieser suspensionen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties